Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Bruno Halpern & Marcio C. Mancini. (2017) Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. Expert Opinion on Drug Safety 16:1, pages 27-39.
Read now
Read now
Assumpta Caixàs, Lara Albert, Ismael Capel & Mercedes Rigla. (2014) Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Design, Development and Therapy 8, pages 1419-1427.
Read now
Read now
Mehrul Hasnain & W. Victor R. Vieweg. (2013) Weight Considerations in Psychotropic Drug Prescribing and Switching. Postgraduate Medicine 125:5, pages 117-129.
Read now
Read now
Niki Katsiki, Apostolos I. Hatzitolios & Dimitri P. Mikhailidis. (2011) Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: ‘A new kid on the block’?. Annals of Medicine 43:4, pages 249-258.
Read now
Read now
Victoria Salem & Stephen R Bloom. (2010) Approaches to the pharmacological treatment of obesity. Expert Review of Clinical Pharmacology 3:1, pages 73-88.
Read now
Read now
Articles from other publishers (29)
Sean D. Regnier, William W. Stoops, Joshua A. Lile, Joseph L. AlcornIIIIII, B. Levi Bolin, Anna R. Reynolds, Lon R. Hays, Abner O. Rayapati & Craig R. Rush. (2023) Naltrexone-bupropion combinations do not affect cocaine self-administration in humans. Pharmacology Biochemistry and Behavior 224, pages 173526.
Crossref
Crossref
Roger S. Mcintyre, Leslie Citrome, Hannah Cummings, Mark S. Todtenkopf, Laura A. Tan, Marni White & Sarah Akerman. (2022) Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine. CNS Spectrums, pages 1-12.
Crossref
Crossref
Henry K. Karlsson, Lauri Tuominen, Semi Helin, Paulina Salminen, Pirjo Nuutila & Lauri Nummenmaa. (2021) Mesolimbic opioid-dopamine interaction is disrupted in obesity but recovered by weight loss following bariatric surgery. Translational Psychiatry 11:1.
Crossref
Crossref
Walter Milano, Valeria De Biasio, Walter Di Munzio, Giuseppina Foggia & Anna Capasso. (2020) Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy. Endocrine, Metabolic & Immune Disorders - Drug Targets 20:8, pages 1232-1243.
Crossref
Crossref
Fernando B. de Moura, Stephen J. Kohut & Jack Bergman. 2019. Neuropsychotherapeutics. Neuropsychotherapeutics
197
236
.
Carl A. Roberts, Paul Christiansen & Jason C. G. Halford. (2017) Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?. Acta Diabetologica 54:8, pages 715-725.
Crossref
Crossref
Sarah Kim. (2016) Drugs to treat obesity: do they work?. Postgraduate Medical Journal 92:1089, pages 401-406.
Crossref
Crossref
Sean Wharton. (2016) Current Perspectives on Long-term Obesity Pharmacotherapy. Canadian Journal of Diabetes 40:2, pages 184-191.
Crossref
Crossref
Margaret Haney, Divya Ramesh, Andrew Glass, Martina Pavlicova, Gillinder Bedi & Ziva D Cooper. (2015) Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers. Neuropsychopharmacology 40:11, pages 2489-2498.
Crossref
Crossref
Ashish Kumar Kakkar & Neha Dahiya. (2015) Drug treatment of obesity: Current status and future prospects. European Journal of Internal Medicine 26:2, pages 89-94.
Crossref
Crossref
Elizabeth Murray, Sietske Brouwer, Rob McCutcheon, Catherine J. Harmer, Philip J. Cowen & Ciara McCabe. (2014) Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity. Psychopharmacology 231:22, pages 4323-4335.
Crossref
Crossref
Steven J. Tobin, Eliedonna E. Cacao, Daniel Wing Wo Hong, Lars Terenius, Vladana Vukojevic & Tijana Jovanovic-Talisman. (2014) Nanoscale Effects of Ethanol and Naltrexone on Protein Organization in the Plasma Membrane Studied by Photoactivated Localization Microscopy (PALM). PLoS ONE 9:2, pages e87225.
Crossref
Crossref
Bruno Halpern, Gustavo Daher & Alfredo Halpern. 2014. Endocrinology and Diabetes. Endocrinology and Diabetes
503
520
.
Cheri L. Deal, Michèle Tony, Charlotte Höybye, David B. Allen, Maïthé Tauber & Jens Sandahl Christiansen. (2013) Growth Hormone Research Society Workshop Summary: Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi Syndrome. The Journal of Clinical Endocrinology & Metabolism 98:6, pages E1072-E1087.
Crossref
Crossref
Pauline Dodet, Serge Perrot, Lauriane Auvergne, Aline Hajj, Guy Simoneau, Xavier Declèves, Christine Poitou, Jean-Michel Oppert, Katel Peoc’h, Stéphane Mouly, Jean-François Bergmann & Célia Lloret-Linares. (2013) Sensory Impairment in Obese Patients? Sensitivity and Pain Detection Thresholds for Electrical Stimulation After Surgery-induced Weight Loss, and Comparison With a Nonobese Population. The Clinical Journal of Pain 29:1, pages 43-49.
Crossref
Crossref
Waleed O. Farid, Andrew J. Lawrence, Elena V. Krstew, Robert J. Tait, Gary K. Hulse & Sarah A. Dunlop. (2012) Maternally Administered Sustained-Release Naltrexone in Rats Affects Offspring Neurochemistry and Behaviour in Adulthood. PLoS ONE 7:12, pages e52812.
Crossref
Crossref
Adarsh K. Gupta. (2012) Diabetes obesity link: how to lower your risk of diabetes with weight management. Osteopathic Family Physician 4:5, pages 149-154.
Crossref
Crossref
John C. Clapham. (2012) Central control of thermogenesis. Neuropharmacology 63:1, pages 111-123.
Crossref
Crossref
James Rippe & Theodore AngelopoulosRaymond Bourey & Charles Lambert. 2012. Obesity. Obesity
155
182
.
Clifford J Bailey & Caroline Day. (2012) Anti-obesity fixed-dose combinations. The British Journal of Diabetes & Vascular Disease 12:1, pages 2-5.
Crossref
Crossref
Mary Ann Pelleymounter, Yuren Wang & Ning Lee. 2011. Peptide Drug Discovery and Development. Peptide Drug Discovery and Development
245
268
.
Albert Stuart Reece. (2011) Hypothalamic opioid–Melanocortin appetitive balance and addictive craving. Medical Hypotheses 76:1, pages 132-137.
Crossref
Crossref
Cunyu Zhang, Susan M. Westaway, Jason D. Speake, Michael J. Bishop, Aaron S. Goetz, Luz Helena Carballo, Mike Hu & Andrea H. Epperly. (2011) Tetrahydroquinoline derivatives as opioid receptor antagonists. Bioorganic & Medicinal Chemistry Letters 21:2, pages 670-676.
Crossref
Crossref
George L. Blackburn, Kristina Spellman & Samuel Wollner. 2011. Preventive Cardiology: Companion to Braunwald's Heart Disease. Preventive Cardiology: Companion to Braunwald's Heart Disease
317
330
.
André M. Faria, Marcio C. Mancini, Maria Edna de Melo, Cintia Cercato & Alfredo Halpern. (2010) Progressos recentes e novas perspectivas em farmacoterapia da obesidade. Arquivos Brasileiros de Endocrinologia & Metabologia 54:6, pages 516-529.
Crossref
Crossref
Bruno Halpern, Eduardo S. L. Oliveira, André M. Faria, Alfredo Halpern, Maria Edna de Melo, Cintia Cercato & Marcio C. Mancini. (2010) Combinations of drugs in the Treatment of Obesity. Pharmaceuticals 3:8, pages 2398-2415.
Crossref
Crossref
Jason C. G. Halford, Emma J. Boyland, John E. Blundell, Tim C. Kirkham & Joanne A. Harrold. (2010) Pharmacological management of appetite expression in obesity. Nature Reviews Endocrinology 6:5, pages 255-269.
Crossref
Crossref
Lee M. Kaplan. (2010) Pharmacologic Therapies for Obesity. Gastroenterology Clinics of North America 39:1, pages 69-79.
Crossref
Crossref
Cassidy VuongStan H. M. Van UumLaura E. O'DellKabirullah Lutfy & Theodore C. Friedman. (2010) The Effects of Opioids and Opioid Analogs on Animal and Human Endocrine Systems. Endocrine Reviews 31:1, pages 98-132.
Crossref
Crossref